


A Note from Brookline Capital Markets

Commending Genelux Corporation for its Recent Successful Issuances

Genelux Corporation ("Genelux"), a clinical-stage immunotherapy company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types, will have raised over \$65 million this year between its IPO and following the final closings of both of its previously announced private placements.

Genelux, which priced its initial public offering at \$6.00 per share and went public on January 26th of this year, intends to use the net proceeds from these offerings to advance clinical programs, including its Phase 3 registrational trial of Olvi-Vec in patients with platinum-resistant/refractory ovarian cancer, and for working capital and general corporate purposes.

On June 27, 2023, the company's stock closed at \$32.20 per share. This remarkable debut, generating returns of **5.4x** offer price, makes Genelux one of the best performing life sciences IPOs in the first 5 months of trading since 2000. Notably, the company joined the Russell 2000 & 3000 indexes on June 26, 2023 after only 5 months of trading.



On **January 25, 2023**, Genelux priced its initial public offering of 2,653,000 shares at a price to the public of **\$6.00 per share**, for total gross proceeds of \$15.9 million. Genelux's most recent close of **\$32.20** on June 27, 2023 represents a return of **5.4x** deal price for this offering.

Brookline Capital Markets acted as a joint-bookrunning manager for this offering.



On **May 15, 2023**, Genelux announced a private placement for 1,665,247 shares of the Company's common stock at a purchase price of **\$20.00 per share**, for gross proceeds of approximately \$33 million. Genelux's most recent close of **\$32.20** on June 27, 2023 represents a return of **1.6x** deal price for this offering.

Brookline Capital Markets acted as a financial advisor for this offering.

The initial closing of this private placement, approximately \$18 million in the aggregate, occurred on May 19, 2023. Additional funds in the amount of approximately \$15 million will be invested on or before November 15, 2023 at the same price as the initial closing investments.



On **June 12, 2023**, Genelux announced a private placement for 900,000 shares of the Company's common stock at a purchase price of **\$20.00 per share**, for gross proceeds of approximately \$18 million. Genelux's most recent close of **\$32.20** on June 27, 2023 represents a return of **1.6x** deal price for this offering.

Brookline Capital Markets acted as a financial advisor for this offering.

The initial closing of this private placement, approximately \$5.5 million, occurred on June 20, 2023. Additional funds in the amount of approximately \$12.5 million will be invested on or before November 15, 2023 at the same price as the initial closing investments.

At Brookline, we pride ourselves on our ability to partner with private corporate clients from inception to IPO. We have established a market-leading platform in the pre-IPO healthcare investment banking arena. Our premier public capital markets franchise dedicates itself to raising capital in the IPO, follow-on, PIPE and convertible markets, as well as to providing capital markets advisory services to its roster of clients.

We stand ready to provide value-added investment banking advice, analysis, and execution for our healthcare corporate clients at any point of clinical development or financial maturity.

** Obtained from sources believed to be reliable including: FactSet, SEC filings and the Company website*

Legal Disclaimer

This publication is prepared by the Equities Department of Brookline Capital Markets, a division of Arcadia Securities, LLC ("Brookline") and is not the product of Brookline's Equity Research Department. This publication is provided for informational purposes only, and it is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.

This publication contains market prices, statistical data and other information (collectively, "Information") from third-party sources believed by Brookline to be reliable. Such Information, however, is neither all-inclusive nor guaranteed or warranted by Brookline to be accurate or complete, and it should not be relied upon as such. Such Information is also subject to change, without notice, and Brookline does not undertake to advise recipients of this publication of changes, if any. Past performance is not a guarantee of future results, and Brookline makes no representation or warranty, express or implied, in respect of future performance of any security (or any grouping of securities) mentioned in this publication. The price of the securities mentioned in this publication and the income they produce may fluctuate and/or be adversely affected by, among other things, exchange rates and/or market conditions, and investors may realize losses on investments in such securities, including the loss of investment principal. Brookline accepts no liability for any loss arising from the use of information contained in this publication, except to the extent that liability may arise under specific statutes or regulations applicable to Brookline.

In the course of its regular business, Brookline may be long or short in the securities mentioned in this publication and may make purchases and/or sales of them or options to purchase or sell them from time to time in the open market, as a market maker or otherwise, including purchases from or sales to customers on a principal basis. In addition, Brookline may perform or seek to perform investment banking services for the issuers of the securities mentioned in this publication in the next three months and has received compensation for such services within the last 12 months.

Member FINRA and SIPC

© 2023 Brookline Capital Markets. All rights reserved. Unauthorized use, distribution, duplication or disclosure without the prior written permission of Brookline in each instance is prohibited.